Vetoquinol (VETO)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 79.70 |
|---|---|
| 52-week range | 65.70 – 91.50 |
| Return, 1 month / 3 months | +5.6% / +12.6% |
| Return, 1 year / 3 years | +3.2% / +2.9% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -26.4% |
| Average daily value traded | 0.71M EUR |
| Dividend yield | 1.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vetoquinol is a French animal health company based in Lure that develops and markets veterinary medicines and related products. It serves veterinarians and livestock producers with anti-infective and antiparasitic treatments, specialty medicines and nutritional products for companion animals such as dogs and cats, and for farm animals including cattle, pigs and poultry. The company operates through its own subsidiaries and distributors, supplying veterinary practices and agricultural customers in France and in markets abroad.
Vetoquinol trades under the code VETO on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vetoquinol (VETO) trades on the Euronext Paris in France. It last closed at EUR 79.70 on 23 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 120 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.2% and over the last three months it rose 12.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.3% | ||
| From 52-week high | -12.4% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.6% | ||
| 6-month return | 0.2% | ||
| 12-month return, skipping the last month | -2.3% | ||
| Stability (higher is calmer) | 70 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.4% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 0.71M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 33 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.2% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.8% |
|---|---|
| 1 month | +5.6% |
| 3 months | +12.6% |
| 6 months | +0.2% |
| 1 year | +3.2% |
| 3 years | +2.9% |
| 5 years | −42.6% |
Signals
| 50-day / 200-day average | 73.86 / 75.68 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.88 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | EUR 0.9300 |
| 4 Jun 2025 | EUR 0.8900 |
| 4 Jun 2024 | EUR 0.8500 |
| 2 Jun 2023 | EUR 0.8000 |
| 3 Jun 2022 | EUR 0.8000 |
| 4 Jun 2021 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.